Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Larimar Therapeutics ( (LRMR) ).
On June 23, 2025, Larimar Therapeutics updated its corporate presentation, highlighting the progress of its clinical-stage protein replacement therapy, nomlabofusp. The therapy, which has received multiple regulatory designations, is part of the FDA’s START pilot program and aims for accelerated approval by 2026. The company plans to expand its clinical trials and introduce a stable, room-temperature formulation, with significant data releases expected in September 2025. Larimar’s efforts could position it as a leader in FA treatment, potentially offering the first disease-modifying therapy for this rare condition.
The most recent analyst rating on (LRMR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. operates in the biotechnology industry, focusing on developing novel therapies for rare diseases. Its primary product, nomlabofusp (CTI-1601), is designed to treat Friedreich’s ataxia (FA) by addressing frataxin deficiency, a significant unmet medical need.
Average Trading Volume: 1,234,625
Technical Sentiment Signal: Sell
Current Market Cap: $165.8M
For detailed information about LRMR stock, go to TipRanks’ Stock Analysis page.